Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 2
1995 1
1997 7
2000 1
2002 1
2003 2
2004 2
2005 4
2006 1
2007 4
2008 3
2009 3
2010 8
2011 5
2012 4
2013 5
2014 4
2015 2
2016 2
2017 5
2018 2
2019 2
2020 3
2021 5
2022 2
2023 3
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study.
Kerstjens HAM, Maspero J, Chapman KR, van Zyl-Smit RN, Hosoe M, Tanase AM, Lavecchia C, Pethe A, Shu X, D'Andrea P; IRIDIUM trial investigators. Kerstjens HAM, et al. Among authors: hosoe m. Lancet Respir Med. 2020 Oct;8(10):1000-1012. doi: 10.1016/S2213-2600(20)30190-9. Epub 2020 Jul 9. Lancet Respir Med. 2020. PMID: 32653074 Clinical Trial.
Mometasone/Indacaterol/Glycopyrronium (MF/IND/GLY) and MF/IND at Different MF Strengths versus Fluticasone Propionate/Salmeterol Xinafoate (FLU/SAL) and FLU/SAL+ Tiotropium in Patients with Asthma.
van Zyl-Smit RN, Chapman KR, Kerstjens HAM, Gessner C, Sagara H, Tanase AM, Hosoe M, Pethe A, Lawrence D, Tillmann HC, D'Andrea P. van Zyl-Smit RN, et al. Among authors: hosoe m. J Asthma Allergy. 2023 Jan 20;16:123-134. doi: 10.2147/JAA.S392975. eCollection 2023. J Asthma Allergy. 2023. PMID: 36714049 Free PMC article. Review.
A Review of the Unique Drug Development Strategy of Indacaterol Acetate/Glycopyrronium Bromide/Mometasone Furoate: A First-in-Class, Once-Daily, Single-Inhaler, Fixed-Dose Combination Treatment for Asthma.
Brittain D, D'Andrea P, Gruen E, Hosoe M, Jain D, Jauernig J, Pethe A, Scosyrev E, Tanase AM, Tillmann HC. Brittain D, et al. Among authors: hosoe m. Adv Ther. 2022 Jun;39(6):2365-2378. doi: 10.1007/s12325-021-02025-w. Epub 2022 Jan 24. Adv Ther. 2022. PMID: 35072888 Free PMC article. Review.
Efficacy of once-daily, single-inhaler, fixed-dose combination of mometasone/indacaterol/glycopyrronium in patients with asthma with or without persistent airflow limitation: Post hoc analysis from the IRIDIUM study.
Van Zyl-Smit RN, Kerstjens HA, Maspero JF, Kostikas K, Hosoe M, Tanase AM, D'Andrea P, Mezzi K, Brittain D, Lawrence D, Chapman KR. Van Zyl-Smit RN, et al. Among authors: hosoe m. Respir Med. 2023 May;211:107172. doi: 10.1016/j.rmed.2023.107172. Epub 2023 Mar 9. Respir Med. 2023. PMID: 36906187 Free article.
Pharmacokinetics of mometasone furoate delivered via two dry powder inhalers.
Vaidya S, Ziegler D, Tanase AM, Malmqvist U, Kanniess F, Hederer B, Hosoe M. Vaidya S, et al. Among authors: hosoe m. Pulm Pharmacol Ther. 2021 Oct;70:102019. doi: 10.1016/j.pupt.2021.102019. Epub 2021 Mar 23. Pulm Pharmacol Ther. 2021. PMID: 33771722 Free article. Clinical Trial.
Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.
Scosyrev E, van Zyl-Smit R, Kerstjens H, Gessner C, Kornmann O, Jain D, Aubrun E, D'Andrea P, Hosoe M, Pethe A, Brittain D. Scosyrev E, et al. Among authors: hosoe m. Respir Med. 2021 Apr-May;180:106311. doi: 10.1016/j.rmed.2021.106311. Epub 2021 Jan 27. Respir Med. 2021. PMID: 33711782 Free article.
76 results